SOCS-4 inhibitors belong to a distinctive class of chemical compounds that primarily target the Suppressors of Cytokine Signaling 4 (SOCS-4) proteins within the cellular signaling pathways. The SOCS family of proteins plays a crucial role in regulating the immune system and maintaining homeostasis by controlling the intensity and duration of cytokine signals. SOCS-4, specifically, is involved in modulating various cellular responses, including immune reactions and inflammatory processes. The inhibitors designed for SOCS-4 typically exert their effects by disrupting the normal functioning of this protein, thereby influencing downstream signaling cascades.
SOCS-4 inhibitors are characterized by specific structural motifs that enable them to interact selectively with the SOCS-4 protein. These inhibitors often feature binding pockets and functional groups that allow them to competitively bind to the active sites of SOCS-4, preventing its interaction with target proteins or substrates. By interfering with the normal regulatory function of SOCS-4, these inhibitors have the potential to modulate immune responses and inflammatory pathways, making them intriguing candidates for further research in understanding cellular signaling mechanisms. The development and exploration of SOCS-4 inhibitors contribute significantly to the broader field of chemical biology, offering insights into the intricacies of immune regulation and providing a foundation for potential applications in modulating cellular responses for various research purposes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
JAK2 inhibitor that can reduce STAT activation and thus indirectly affect SOCS4 function. | ||||||
Stat3 Inhibitor III, WP1066 | 857064-38-1 | sc-203282 | 10 mg | $132.00 | 72 | |
Targets JAK2 and inhibits STAT3 phosphorylation, possibly limiting SOCS4-related feedback loops. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1 and JAK2 inhibitor, can downregulate STAT signaling upstream of SOCS4. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Inhibits JAK1 and JAK2, potentially altering the pathway that includes SOCS4. | ||||||
Cucurbitacin I | 2222-07-3 | sc-203010 | 1 mg | $250.00 | 9 | |
Inhibits STAT3 phosphorylation, thereby may influence SOCS4 indirectly. | ||||||
Stat3 Inhibitor VI, S3I-201 | 501919-59-1 | sc-204304 | 10 mg | $151.00 | 104 | |
Inhibits STAT3 dimerization, potentially impacting SOCS4's modulation of the pathway. | ||||||
Pimozide | 2062-78-4 | sc-203662 | 100 mg | $104.00 | 3 | |
STAT5 inhibitor that could affect pathways regulating SOCS4. | ||||||
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $156.00 $339.00 | 59 | |
JAK inhibitor that can alter STAT phosphorylation and thus impact SOCS4 dynamics. | ||||||